The trial will test four dose levels and include up to 18 patients with advanced, FLT3-expressing acute myeloid leukemia.

The firm aims to use its platform to guide selection of personalized and immunotherapies for cancer patients and to support drug development.

Pfizer opted to discontinue the product for "several reasons," including limited interest from patients and physicians in gene therapies for hemophilia.

The firm will test additional doses and use its proprietary drug response predictor to gather data that can inform a registrational study.

The biotech has met with UK regulators to discuss a marketing authorization application under exceptional circumstances based on data from 11 patients.

The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.

A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...

Researchers will launch a randomized clinical trial to assess whether PGx-guided care helps keep patients out of the ER and ...

Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the ...

Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.

The registrational trial will include 212 patients who are newly diagnosed with advanced head and neck cancer.

In a previous trial, patients with RSK2-high cancers had a significantly greater benefit from treatment with PMD-026 than those with RSK2-low cancers.